BioTuesdays

Category - News

MacroGenics Logo
Developments

MacroGenics submits margetuximab BLA to the FDA

MacroGenics (NASDAQ:MGNX) submitted a biologics license application (BLA) for margetuximab for the treatment of patients with metastatic HER2-positive breast cancer. The submission is based on the safety and efficacy...

December 19, 2019
Developments

Season’s Greetings (and JPM 2020)

Wow, what an interesting year 2019 has turned out to be!On behalf of everyone at BioTuesdays, I would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and...

December 19, 2019
Mesoblast Logo
Markets

Dawson James starts Mesoblast at buy; PT $14

Dawson James Securities initiated coverage of Mesoblast (NASDAQ:MESO; ASX:MSB) with a “buy” rating and $14 price target. The stock closed at $7.42 on Dec. 18. Mesoblast is using its proprietary technology platform to...

December 19, 2019
X4 Pharma
Markets

Roth starts X4 Pharma at buy; PT $20

Roth Capital Partners launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $20 price target. The stock closed at $11 on Dec. 17. Analyst Zegbeh Jallah writes that her investment thesis is based...

December 18, 2019
Aduro Biotech
Markets

Analysts downgrade and lower PTs for Aduro Biotech

William Blair downgraded Aduro Biotech (NASDAQ:ADRO) to “market perform” from “outperform” and H.C. Wainwright cut its price target for Aduro after Novartis removed Aduro’s intratumoral STING agonist, ADU-S100, from its...

December 18, 2019
Diffusion Pharma Logo
Markets

HCW cuts Diffusion Pharma PT to $3.50 on dilution

H.C. Wainwright lowered its price target for Diffusion Pharmaceuticals (NASDAQ:DFFN) to $3.50 from $10, reflecting dilution from two recent financings. The stock closed at 41 cents on Dec. 17. Analyst Swayampakula...

December 18, 2019